On September 12, 2023, Ad Scientiam, a global leader in digital biomarkers has announced the launch of MS-DETECT, an international, multicenter, longitudinal study, supported by Sanofi. MS- DETECT aims to evaluate the ability of MSCopilot®, a software as medical device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam’s expertise in MS and will recruit 314 patients in the United States, Canada, Germany, Italy, Spain, Denmark and France.
English 
French